Skip to main content
Home

Primary Menu

  • OUR STRATEGY
    • HOW WE MAKE CANCER BREAKTHROUGHS
    • WHAT WE SUPPORT
    • OUR HISTORY
    • OUR LEADERSHIP
  • OUR IMPACT
    • WHAT SETS US APART
    • CURRENT PROJECTS
    • TIMELINE
  • GET INVOLVED
    • LEADERSHIP GIFTS
    • BECOME A SPONSOR
    • LEGACY PLANNING
    • EVENTS
  • FOR SCIENTISTS
    • AWARD PROGRAMS
    • APPLICATION GUIDELINES
    • GENERATIONS OF INNOVATORS
    • SELECTION COMMITTEES
    • ACCELERATING CANCER CURES
    • FAQ
  • NEWS
  • BROADWAY TICKETS

Donate

  • DONATE

Damon Runyon News

View New Articles By

News

Scientist Bio February 2, 2023
James Swann, VetMB, DPhil

A key question in cancer biology is how genetic mutations, acquired over time, interact with environmental factors to affect emergence and progression of disease. This is particularly relevant in blood cancers because many people acquire genetic mutations in blood-forming stem cells in the bone marrow but only a small proportion go on to develop acute myeloid leukemia (AML). Dr.

Read More
Scientist Bio February 2, 2023
Mingjian Du, PhD

Global increases in metabolic syndrome, obesity, and diabetes are likely related to the overconsumption of hyper-palatable, cheap, ultra-processed food containing high amounts of added sugar and fat. Intriguingly, the vagus nerve has been discovered as the key conduit relaying information about sugar or fat ingestion from the gut to the brain, where a preference for sugar or fat is then developed and reinforced. Dr.

Read More
Scientist Bio February 2, 2023
Christopher Noetzel, PhD

As different tissues in the body form, cells need to undergo a complex, precisely timed series of differentiation programs to form specialized cell types. Importantly, premature or delayed initiation of these programs can contribute to cancer formation. However, how timing of cellular differentiation is encoded on a molecular level is poorly understood. Dr. Noetzel is using the protozoan parasite Cryptosporidium parvum as a simplified model of eukaryotic differentiation.

Read More
Scientist Bio February 2, 2023
James Osei-Owusu, PhD

The relaxin-2 receptor (RXFP1), which binds a hormone aptly known as relaxin, plays a key role in reproductive and cardiovascular physiology by increasing blood flow and facilitating childbirth. Abnormal signaling of the receptor leads to a variety of cancers, particularly tumors of reproductive tissues. James aims to establish a comprehensive understanding of RXFP1 molecular signaling and how it can be inhibited for cancer treatment. This study will facilitate the discovery of candidate therapeutic agents as well as aid the rational design of drugs for reproductive cancer treatment. Dr.

Read More
Scientist Bio February 2, 2023
Archana Krishnamoorthy, PhD

Cancer initiation and progression stems from cell division errors that promote chromosome breakage and accumulation of mutations. Dr. Krishnamoorthy [HHMI Fellow] will use cutting-edge, cross-disciplinary approaches to provide insights into the fundamental question of how cell division shapes the cancer genome. Understanding the mechanisms of cancer genome complexity will help identify better diagnostics and treatments for cancers linked with high levels of genome alterations. Dr.

Read More
Scientist Bio February 2, 2023
Joshua B. Sheetz, PhD

Cancer cells adapt their metabolism to achieve rapid growth and proliferation. Much of their metabolic malleability hinges on mitochondria, subcellular hubs for energy transformation and biosynthesis. As a key means to control mitochondrial composition and meet metabolic demands, cells mark mitochondrial proteins for degradation by a process called ubiquitylation. How both cancerous and healthy cells direct and monitor mitochondrial ubiquitylation remains poorly understood. Dr.

Read More
Scientist Bio February 2, 2023
Ben F. Brian, PhD

Abnormal interactions between our immune system and our gut microbes can lead to inflammation that drives colon and gastric cancer growth. Dr. Brian [HHMI Fellow] is investigating how the immune system recognizes and responds to these microbes, and how these interactions contribute to abnormal inflammation that can fuel cancer growth. Microbiota-immune interactions have been generally studied in the context of "clean" laboratory mice, but these models do not fully capture human immunology and the complex interplay between host cells and foreign microbes. To overcome this, Dr.

Read More
Scientist Bio February 2, 2023
Ryan Y. Muller, PhD

The PABPC1 protein has diverse roles in gene expression control that span functions in mRNA stability, polyA tail length control, and translation regulation. PABPC1 gene amplifications are detected in roughly 4% of cancer samples, but it is unclear how PABPC1 fits into the picture of cancer progression. Dr. Muller [HHMI Fellow] studies the sequence preferences of PABPC1 protein to understand the mechanistic details that determine which transcripts are subject to PABPC1-mediated regulation.

Read More
Scientist Bio February 1, 2023
Hui (Vivian) Chiu, PhD

Fatigue is the most common symptom experienced by patients with cancer or undergoing cancer treatment. While chronic inflammation and hormonal imbalance have been suggested as possible causes, the roots of cancer-related fatigue remain unclear and thus we lack effective treatments. Dr. Chiu [HHMI Fellow] seeks to illuminate the physiological basis of fatigue using interdisciplinary approaches that combine the strengths of neuroscience, immunology, and computational biology. Through the lens of brain-body interactions, Dr.

Read More
Scientist Bio February 1, 2023
Erik Van Dis, PhD

The innate immune system is the body's first line of defense against pathogens. The innate immune sensor MDA5 detects nucleic acids derived from pathogenic genomes or damaged cells and drives the production of cytokines, an important signaling molecule in the immune inflammatory response. MDA5 can be aberrantly activated by host nucleic acids, however, leading to autoimmune activation. Hyperactive MDA5 alleles are associated with the development of autoimmune diabetes. Dr.

Read More

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • …
  • Next page Next ›
  • Last page Last »

ABOUT

Annual Reports + Report Cards
Financial Overview
Our Team

CONNECT

1.877.7CANCER
info@damonrunyon.org
One Exchange Plaza
55 Broadway, Suite 302
New York, NY 10006

Damon Runyon Cancer Research Foundation on Facebook Damon Runyon Cancer Research Foundation on LinkedIn Damon Runyon Cancer Research Foundation on BlueSky Damon Runyon Cancer Research Foundation on X Damon Runyon Cancer Research Foundation on Instagram Damon Runyon Cancer Research Foundation on Youtube

    

© COPYRIGHT DAMON RUNYON. ALL RIGHTS RESERVED

PRIVACY POLICY